June 20, 2019

Eight Years And $83 Million Later, Syqe® Medical Releases First Cannabis Inhaler

Teva will market the company’s inhalers exclusively in Israel, after signing a marketing and distribution agreement with Syqe® in 2016.

Syqe® Begins Marketing Medical Cannabis Inhaler

The new inhaler, which allows doctors to prescribe precise dosages, has received Ministry of Health approval in Israel.

Study Finds Medical Cannabis Reduces Cancer Patients’ Pain And Need For Opiates

25/05/2022

Researchers in Israel found that the use of medical cannabis reduced cancer patients’ pain and use of painkillers in a recently published study.

Syqe® Medical Announces Agreement with Israeli Ministry of Defence to Provide the SyqeAir Technology to Veterans

15/02/2023

Syqe® Medical signed a first-of-its-kind agreement with the Israeli Ministry of Defense to supply the groundbreaking SyqeAir Inhaler and Cartridges to all veterans prescribed medical cannabis.

Cannabis Inhaler Company Syqe® Medical Raises $50 Million

01/01/2019

Syqe® develops a pocket-sized metered-dose inhaler designed for precise delivery of cannabis molecules.

Medical Cannabis

SyqeAir Inhaler

Useful Information

Media

Contact Syqe®

Phone. +972-3-376-7338
Email. info@syqemed.com
Syqe® Israel. syqe.co.il

Show Us Some Love

The site and the content therein are provided for general knowledge only and do not constitute advertising and/or medical, pharmacological, or professional advice, diagnosis, treatment, or other healthcare services that in any way generate a doctor-patient relationship and/or recommendation for treatment or products in general, and for medical cannabis products and/or SyqeAir inhaler in particular. You should make all medical or health-related decisions on the basis of professional advice from a licensed physician or qualified healthcare professional who is fully aware of your individual circumstances. For any questions regarding products, including medical cannabis products and/or the SyqeAir inhaler, please consult your attending physician and/or the pharmacist at the dispensing pharmacy. The use and reliance on all content appearing on this site are at your sole responsibility, and Syqe® will not be responsible for any decision or action taken by you as a result of relying on this site.

Day: June 20, 2019

Eight Years And $83 Million Later, Syqe® Medical Releases First Cannabis Inhaler

Syqe® Begins Marketing Medical Cannabis Inhaler

Related Posts

Study Finds Medical Cannabis Reduces Cancer Patients’ Pain And Need For Opiates

Syqe® Medical Announces Agreement with Israeli Ministry of Defence to Provide the SyqeAir Technology to Veterans

Cannabis Inhaler Company Syqe® Medical Raises $50 Million